Amyloid‐β sequester proteins as blood‐based biomarkers of cognitive decline. Issue 2 (15th June 2015)

• Record Type: Journal Article
• Authors: Uchida, Kazuhiko; Shan, Liu; Suzuki, Hideaki; Tabuse, Yo; Nishimura, Yoshinori; Hirokawa, Yoshihiro; Mizukami, Katsuyoshi; Akatsu, Hiroyasu; Meno, Kohji; Asada, Takashi
• Is Part Of: Alzheimer's & dementia. Volume 1:Issue 2(2015)
• Page Start: 270
• Page End: 280
• Publication Date: 2015-06-15
• Subjects: Alzheimer's disease -- Apolipoprotein -- Biomarker -- Complement system -- Diagnostics -- Mild cognitive impairment -- Transthyretin; Alzheimer's disease -- Periodicals; Alzheimer's disease -- Diagnosis -- Periodicals; Dementia -- Periodicals; Dementia -- Diagnosis -- Periodicals; 616.831
• DOI: 10.1016/j.dadm.2015.04.003
• Languages: English
• ISSNs: 2352-8729

Abstract

Abstract: Introduction: There are no blood‐based biomarkers for cognitive decline in aging, or mild cognitive impairment (MCI) and Alzheimer's disease (AD). Cumulative evidence suggests that apolipoproteins, complement system, and transthyretin are involved in AD pathogenesis by sequestration of amyloid β. However, there is no clinical study to assess the utility of "sequester proteins" in risk assessment and/or diagnosis of MCI and AD. Methods: Serum levels of sequester proteins and their clinical potential in cognitive decline assessment were analyzed by longitudinal and cross‐sectional studies using independent cohorts and were confirmed by a prospective study. Results: A combination of apolipoprotein A1, complement C3, and transthyretin achieved an area under the curve of 0.89 (sensitivity 91% and specificity 80%) in MCI versus healthy controls and also discriminated individuals with mild cognitive decline from healthy controls. Discussion: A set of sequester proteins could be blood‐based biomarkers for assessment of early stages of cognitive decline.